Comparative Pharmacology
Head-to-head clinical analysis: METHAMPEX versus METHYLIN ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHAMPEX versus METHYLIN ER.
METHAMPEX vs METHYLIN ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methamphetamine is a sympathomimetic amine that increases synaptic concentrations of dopamine, norepinephrine, and serotonin by promoting their release from presynaptic terminals and inhibiting their reuptake. It also inhibits monoamine oxidase, reducing neurotransmitter catabolism.
Methylphenidate is a central nervous system stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their availability in the synaptic cleft.
150 mg orally twice daily for 12 weeks; alternative: 90 mg orally twice daily if tolerability issues.
20-60 mg orally once daily in the morning
None Documented
None Documented
Terminal elimination half-life is approximately 9-14 hours in adults with normal renal function (mean ~12 hours). In children, half-life is shorter (~8-10 hours). Context: Steady-state is achieved within 2-3 days. Half-life may be prolonged in patients with renal impairment (up to 20-30 hours) or alkaline urine (up to 30 hours).
Mean 3-6 hours in adults; longer in children (4-8 hours). Clinical context: steady-state reached within 2 days; dosing every 8-12 hours.
Primarily renal excretion (≥90% as unchanged drug and metabolites); approximately 70-80% as unchanged amphetamine, 10-15% as deaminated metabolites (hippuric acid, benzoic acid). Biliary/fecal excretion is negligible (<5%). Renal clearance is pH-dependent; acidic urine increases elimination. In overdose or renal impairment, elimination half-life may prolong.
Renal (90% as metabolites, <1% unchanged). Biliary/fecal: <2%.
Category C
Category C
CNS Stimulant
CNS Stimulant